VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced the funding and initiation… Read More
PNI will use the investment to advance a cost-effective Made-in-Canada COVID-19 vaccine PNI offers expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing PNI will contribute to… Read More
– Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – – Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need… Read More
Vancouver, British Columbia–(Newsfile Corp. – October 21, 2020) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today… Read More
– Adaptive Clinical Trial Platform in Glioblastoma Multiforme – – Expected to serve as basis for VAL-083’s new drug application (NDA) submission and registration – Expansion of clinical site involvement… Read More
